Literature DB >> 21030176

Transarterial Onyx packing of the transverse-sigmoid sinus for dural arteriovenous fistulas.

Chuhan Jiang1, Xianli Lv, Youxiang Li, Zhongxue Wu.   

Abstract

OBJECTIVE: To report transarterial Onyx packing of the transverse-sigmoid sinus for dural arteriovenous fistulae (DAVFs).
METHODS: We retrospectively studied consecutive 5 patients (2 female and 3 male) treated for a transverse-sigmoid sinus DAVF since 2008 in whom transverse sinus packing was attempted with a transarterial approach Onyx embolization. The mean clinical follow-up period was 6.2 months.
RESULTS: Of the five lesions, 2 fistulas were type IIa, 3 were type IIb, according to the Cognard classification. Five Onyx embolizations were all performed via the middle meningeal artery. Cure was obtained in all cases after completion of direct sinus packing. No complications were revealed.
CONCLUSIONS: Transarterial Onyx packing of transverse-sigmoid sinus for DAVFs via the meningeal arterial system is a safe therapeutic alternative in selected cases.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21030176     DOI: 10.1016/j.ejrad.2010.09.045

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  3 in total

1.  Delayed dural arteriovenous fistula after microvascular decompression for hemifacial spasm.

Authors:  Sung Han Kim; Won Seok Chang; Hyun Ho Jung; Jin Woo Chang
Journal:  J Korean Neurosurg Soc       Date:  2014-08-31

2.  Transvenous balloon-assisted transarterial Onyx embolization of transverse-sigmoid dural arteriovenous malformation.

Authors:  Pakrit Jittapiromsak; Léon Ikka; Nidhal Benachour; Laurent Spelle; Jacques Moret
Journal:  Neuroradiology       Date:  2012-11-21       Impact factor: 2.804

3.  Efficacy and limitations of transarterial acrylic glue embolization for intracranial dural arteriovenous fistulas.

Authors:  Naoko Miyamoto; Isao Naito; Tatsuya Shimizu; Yuhei Yoshimoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2015-01-23       Impact factor: 1.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.